Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers

Area of Science:

• Radiation oncology
• Medicinal chemistry
• Drug discovery

Background:

• Stereotactic body radiotherapy (SBRT) use is increasing, potentially leading to greater hypoxic cell radioresistance.
• Nitroimidazole radiosensitisers are regaining clinical interest, particularly for SBRT applications.
• Development of novel radiosensitisers is crucial to overcome treatment resistance.

Purpose of the Study:

• To identify novel nitroimidazole radiosensitisers for overcoming SBRT-induced radioresistance.
• To develop an efficient screening protocol for academic drug discovery laboratories.
• To select promising drug candidates for further preclinical evaluation.

Main Methods:

• Development of an abbreviated screening protocol for rapid triage of compounds.
• Assessment of physicochemical and in vitro properties of potential radiosensitisers.
• Combination of in vitro radiosensitisation data with tumour pharmacokinetic data for candidate selection.

Main Results:

• Identification of a new class of nitroimidazole radiosensitiser.
• Establishment of an expeditious screening protocol suitable for academic settings.
• Efficient selection of drug candidates based on combined efficacy and pharmacokinetic data.

Conclusions:

• A novel nitroimidazole radiosensitiser has been identified.
• An efficient screening protocol facilitates the discovery of radiosensitisers for SBRT.
• This approach enables rapid selection of promising candidates for further development to combat radioresistance in SBRT.